|
1
|
Leconet W, Chentouf M, du Manoir S,
Chevalier C, Sirvent A, Ait-Arsa I, Busson M, Jarlier M,
Radosevic-Robin N, Theillet C, et al: Therapeutic activity of
anti-AXL antibody against triple-negative breast cancer
patient-derived xenografts and metastasis. Clin Cancer Res.
23:2806–2816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gay CM, Balaji K and Byers LA: Giving AXL
the axe: Targeting AXL in human malignancy. Br J Cancer.
116:415–423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duan Y, Luo L, Qiao C, Li X, Wang J, Liu
H, Zhou T, Shen B, Lv M and Feng J: A novel human anti-AXL
monoclonal antibody attenuates tumour cell migration. Scand J
Immunol. 90:e127772019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Myers SH, Brunton VG and Unciti-Broceta A:
AXL inhibitors in cancer: A Medicinal Chemistry Perspective. J Med
Chem. 59:3593–3608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colavito SA: AXL as a target in breast
cancer therapy. J Oncol. 2020:52919522020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leconet W, Larbouret C, Chardes T, Thomas
G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugniere M,
Bernex F, et al: Preclinical validation of AXL receptor as a target
for antibody-based pancreatic cancer immunotherapy. Oncogene.
33:5405–5414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iida S, Miki Y, Suzuki T, Mori K, Saito M,
Niikawa H, Kondo T, Yamada-Okabe H and Sasano H: Activation of AXL
and antitumor effects of a monoclonal antibody to AXL in lung
adenocarcinoma. Anticancer Res. 34:1821–1827. 2014.PubMed/NCBI
|
|
8
|
Wei J, Sun H, Zhang A, Wu X, Li Y, Liu J,
Duan Y, Xiao F, Wang H, Lv M, et al: A novel AXL chimeric antigen
receptor endows T cells with anti-tumor effects against triple
negative breast cancers. Cell Immunol. 331:49–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oien DB, Garay T, Eckstein S and Chien J:
Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324
enhances mesothelioma cell death from chemotherapy. Front
Pharmacol. 8:9702018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong J, Peng D, Chen Z, Sehdev V and
Belkhiri A: ABL regulation by AXL promotes cisplatin resistance in
esophageal cancer. Cancer Res. 73:331–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hong CC, Lay JD, Huang JS, Cheng AL, Tang
JL, Lin MT, Lai GM and Chuang SE: Receptor tyrosine kinase AXL is
induced by chemotherapy drugs and overexpression of AXL confers
drug resistance in acute myeloid leukemia. Cancer Lett.
268:314–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J,
Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic
target in cancer: Role of Axl in tumor growth, metastasis and
angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Palisoul ML, Quinn JM, Schepers E,
Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH,
Powell MA, et al: Inhibition of the receptor tyrosine kinase AXL
restores paclitaxel chemosensitivity in uterine serous cancer. Mol
Cancer Ther. 16:2881–2891. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ludwig KF, Du W, Sorrelle NB,
Wnuk-Lipinska K, Topalovski M, Toombs JE, Cruz VH, Yabuuchi S,
Rajeshkumar NV, Maitra A, et al: Small-molecule inhibition of axl
targets tumor immune suppression and enhances chemotherapy in
pancreatic cancer. Cancer Res. 78:246–255. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen Y, Chen X, He J, Liao D and Zu X: Axl
inhibitors as novel cancer therapeutic agents. Life Sci.
198:99–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Falcone I, Conciatori F, Bazzichetto C,
Bria E, Carbognin L, Malaguti P, Ferretti G, Cognetti F, Milella M
and Ciuffreda L: AXL receptor in breast cancer: Molecular
involvement and therapeutic limitations. Int J Mol Sci.
21:84192020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheridan C: First Axl inhibitor enters
clinical trials. Nat Biotechnol. 31:775–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen F, Song Q and Yu Q: Axl inhibitor
R428 induces apoptosis of cancer cells by blocking lysosomal
acidification and recycling independent of Axl inhibition. Am J
Cancer Res. 8:1466–1482. 2018.PubMed/NCBI
|
|
19
|
Ye X, Li Y, Stawicki S, Couto S,
Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koopman LA, Terp MG, Zom GG, Janmaat ML,
Jacobsen K, Gresnigt-van den Heuvel E, Brandhorst M, Forssmann U,
de Bree F, Pencheva N, et al: Enapotamab vedotin, an AXL-specific
antibody-drug conjugate, shows preclinical antitumor activity in
non-small cell lung cancer. JCI Insight. 4:e1281992019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahnert JR, Taylor MH, O'Reilly E, Zhang J,
Doebele R, Ben Y, Sharp L, Boyle WJ, Chang CY, Frey G, et al: A
phase 1/2 dose-escalation and expansion study of a conditionally
active anti-AXL humanized monoclonal antibody (BA3011) in patients
with advanced solid tumors. J Clin Oncol. 36 (Suppl
15):TPS121262018. View Article : Google Scholar
|
|
22
|
Duan Y, Hu B, Qiao C, Luo L, Li X, Wang J,
Liu H, Zhou T, Shen B, Lv M and Feng J: Engineered
AXL−ECD-Fc variants that abolish the AXL/Gas6
interaction suppress tumor cell migration. Oncol Lett.
17:5784–5792. 2019.PubMed/NCBI
|
|
23
|
Sasaki T, Knyazev PG, Clout NJ, Cheburkin
Y, Gohring W, Ullrich A, Timpl R and Hohenester E: Structural basis
for Gas6-Axl signalling. EMBO J. 25:80–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki K, Nakamura K, Kato K, Hamada H and
Tsukamoto T: Exploration of target molecules for prostate cancer
gene therapy. Prostate. 67:1163–1173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilson C, Ye X, Pham T, Lin E, Chan S,
McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, et al: AXL
inhibition sensitizes mesenchymal cancer cells to antimitotic
drugs. Cancer Res. 74:5878–5890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
D'Alfonso TM, Hannah J, Chen Z, Liu Y,
Zhou P and Shin SJ: Axl receptor tyrosine kinase expression in
breast cancer. J Clin Pathol. 67:690–696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakhjavani M, Hardingham JE, Palethorpe
HM, Price TJ and Townsend AR: Druggable molecular targets for the
treatment of triple negative breast cancer. J Breast Cancer.
22:341–361. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tovey H and Cheang MCU: Identifying
biomarkers to pair with targeting treatments within triple negative
breast cancer for improved patient stratification. Cancers (Basel).
11:18642019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carey L, Winer E, Viale G, Cameron D and
Gianni L: Triple-negative breast cancer: Disease entity or title of
convenience? Nat Rev Clin Oncol. 7:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W,
Yu M, Lin J and Cui Q: MicroRNAs involved in carcinogenesis,
prognosis, therapeutic resistance and applications in human
triple-negative breast cancer. Cells. 8:14922019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim KC, Baek SH and Lee C:
Curcumin-induced downregulation of Axl receptor tyrosine kinase
inhibits cell proliferation and circumvents chemoresistance in
non-small lung cancer cells. Int J Oncol. 47:2296–2303. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Asiedu MK, Beauchamp-Perez FD, Ingle JN,
Behrens MD, Radisky DC and Knutson KL: AXL induces
epithelial-to-mesenchymal transition and regulates the function of
breast cancer stem cells. Oncogene. 33:1316–1324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heckmann D, Maier P, Laufs S, Li L,
Sleeman JP, Trunk MJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S and
Allgayer H: The disparate twins: A comparative study of CXCR4 and
CXCR7 in SDF-1α-induced gene expression, invasion and
chemosensitivity of colon cancer. Clin Cancer Res. 20:604–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun ZG, Liu JH, Zhang JM and Qian Y:
Research progress of Axl inhibitors. Curr Top Med Chem.
19:1338–1349. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang PW, Liu YC, Chang YH, Lin CC, Huang
PM, Hua KT, Lee JM and Hsieh MS: Cabozantinib (XL184) and R428
(BGB324) inhibit the growth of esophageal squamous cell carcinoma
(ESCC). Front Oncol. 9:11382019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang ZF, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schoumacher M and Burbridge M: Key Roles
of AXL and MER receptor tyrosine kinases in resistance to multiple
anticancer therapies. Curr Oncol Rep. 19:192017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu L, Greger J, Shi H, Liu Y, Greshock J,
Annan R, Halsey W, Sathe GM, Martin AM and Gilmer TM: Novel
mechanism of lapatinib resistance in HER2-positive breast tumor
cells: Activation of AXL. Cancer Res. 69:6871–6878. 2009.
View Article : Google Scholar : PubMed/NCBI
|
